Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-25T01:05:04.340Z Has data issue: false hasContentIssue false
  • English
  • Français

Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects

Published online by Cambridge University Press:  09 March 2007

Kirsten B. Holven ,
Tor S. Haugstad ,
Torbjørn Holm ,
Pål Aukrust ,
Leiv Ose  and
Marit S. Nenseter
Kirsten B. Holven*
Affiliation:
Research Institute for Internal Medicine University Hospital Rikshospitalet, Oslo, Norway The Lipid Clinic, University Hospital Rikshospitalet, Oslo, Norway
Tor S. Haugstad
Affiliation:
Pediatric Research Institute, University Hospital Rikshospitalet, Oslo, Norway
Torbjørn Holm
Affiliation:
Research Institute for Internal Medicine University Hospital Rikshospitalet, Oslo, Norway Department of Cardiology, University Hospital Rikshospitalet, Oslo, Norway
Pål Aukrust
Affiliation:
Research Institute for Internal Medicine University Hospital Rikshospitalet, Oslo, Norway Section of Clinical Immunology and Infection Diseases, Medical Department, University Hospital Rikshospitalet, Oslo, Norway
Leiv Ose
Affiliation:
The Lipid Clinic, University Hospital Rikshospitalet, Oslo, Norway
Marit S. Nenseter
Affiliation:
Research Institute for Internal Medicine University Hospital Rikshospitalet, Oslo, Norway The Lipid Clinic, University Hospital Rikshospitalet, Oslo, Norway Section of Clinical Immunology and Infection Diseases, Medical Department, University Hospital Rikshospitalet, Oslo, Norway
*
*Corresponding author: Dr Kirsten B. Holven, fax +47 2307 3630, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, has been suggested to be a novel risk factor for endothelial dysfunction. It has previously been reported that hyperhomocysteinaemia may be associated with impaired endothelium-dependent vasodilation and reduced plasma level of NO-derived endproducts (NOx). In the present study, plasma levels of arginine and ADMA were measured in twenty-one healthy control subjects, and in twenty-one hyperhomocysteinaemic subjects before and after 6 weeks and 12 months of folic acid supplementation, and compared with previously measured plasma NOx values in the hyperhomocysteinaemic subjects. Compared with control subjects, hyperhomocysteinaemic subjects had higher plasma levels of arginine and ADMA. More importantly, folic acid therapy significantly reduced plasma levels of arginine and ADMA. Furthermore, plasma levels of arginine and ADMA were positively correlated with plasma homocysteine levels and negatively correlated with plasma folate, as well as negatively correlated with plasma NOx. Our results suggest that ADMA may be a mediator of the atherogenic effects of homocysteine.

Keywords

HomocysteineFolic acidAsymmetric dimethylarginineNitric-oxide-derived endproducts
Type
Research Article
Information
British Journal of Nutrition , Volume 89 , Issue 3 , March 2003 , pp. 359 - 363
Copyright
Copyright © The Nutrition Society 2003

References

Bellamy, MF, McDowell, IFW, Ramsey, MW, Brownlee, M, Bones, C, Newcombe, RG & Lewis, MJ (1998) Hyperho-mocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 98, 1848–1852.CrossRefGoogle ScholarPubMed
Bellamy, MF, McDowell, IF, Ramsey, MW, Brownlee, M, Newcombe, RG & Lewis, MJ (1999) Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. European Journal of Clinical Investigation 29, 659–662.CrossRefGoogle ScholarPubMed
Böger, RH, Bode-Böger, SM, Sydow, K, Heistad, DD & Lentz, SR (2000 a) Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocysteinemia or hypercholesterolemia. Arteriosclerosis Thrombosis and Vascular Biology 20, 1557–1564.CrossRefGoogle ScholarPubMed
Böger, RH, Bode-Böger, SM, Szuba, A, Tsao, PS, Chan, JR, Tangphao, O, Blaschke, TF & Cooke, JP (1998) Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 98, 1842–1847.CrossRefGoogle ScholarPubMed
Böger, RH, Bode-Böger, SM, Tsao, PS, Lin, PS, Chan, JR & Cooke, JP (2000 b) An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. Journal of the American College of Cardiology 36, 2287–2295.CrossRefGoogle ScholarPubMed
Böger, RH, Lentz, SR, Bode-Böger, SM, Knapp, HR & Haynes, WG (2001) Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocysteinemia in humans. Clinical Science 100, 161–167.CrossRefGoogle ScholarPubMed
Boushey, CJ, Beresford, SA, Omenn, GS & Motulsky, AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Journal of the American Medical Association 274, 1049–1057.CrossRefGoogle ScholarPubMed
Brattstrom, LE, Israelsson, B, Jeppsson, JO & Hultberg, BL (1988) Folic acid – an innocuous means to reduce plasma homocysteine. Scandinavian Journal of Clinical and Laboratory Investigation 48, 215–221.CrossRefGoogle ScholarPubMed
Chambers, JC, McGregor, A, Jean-Marie, J & Kooner, JS (1998) Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 351, 36–37.CrossRefGoogle Scholar
Department of Health and Human Services (1993) Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Washington, DC: Department of Health and Human Services.Google Scholar
Feng, Q, Lu, X, Fortin, AJ, Pettersson, A, Hedner, T, Kline, RL & Arnold, JMO (1998) Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovascular Research 37, 667–675.CrossRefGoogle ScholarPubMed
Furchgott, RF & Zawadzki, JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373–376.CrossRefGoogle ScholarPubMed
Harker, LA, Slichter, SJ, Scott, CR & Ross, R (1974) Homocystinemia, vascular injury and arterial thrombosis. New England Journal of Medicine 291, 537–543.CrossRefGoogle ScholarPubMed
Holven, KB, Holm, T, Aukrust, P, Christensen, B, Kjekshus, J, Andreassen, AK, Gullestad, L, Hagve, TA, Svilaas, A, Ose, L & Nenseter, MS (2001) Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. American Journal of Medicine 110, 536–542.CrossRefGoogle ScholarPubMed
Kokame, K, Kato, H & Miyata, T (1996) Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP7/iP and novel genes. Journal of Biological Chemistry 271, 29659–29665.CrossRefGoogle Scholar
Lentz, SR, Sobey, CG, Piegors, DJ, Bhopatkar, MY, Faraci, FMM, Malinow, R & Heistad, DD (1996) Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. Journal of Clinical Investigation 98, 24–29.CrossRefGoogle ScholarPubMed
Matsuoka, H, Itoh, S, Kimoto, M, Kohno, K, Tamai, O, Wada, Y, Yasukawa, H, Iwami, G, Okuda, S & Imaizumi, T (1997) Asymmetrical dimethylarginine, an endogenous inhibitor, in experimental hypertension. Hypertension 29, 242–247.CrossRefGoogle ScholarPubMed
Miyazaki, H, Matsuoka, H, Cooke, JP, Usui, M, Ueda, S, Okuda, S & Imaizumi, T (1991) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99, 1141–1146.CrossRefGoogle Scholar
Stuhlinger, MC, Tsao, PS, Her, JH, Kimoto, M, Balint, RF & Cooke, JP (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104, 2569–2575.CrossRefGoogle ScholarPubMed
Tawakol, A, Omland, T, Gerhard, M, Wu, JT & Creager, MA (1997) Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95, 1119–1121.CrossRefGoogle ScholarPubMed
Ubbink, JB, Vermaak, WJH & Bissbort, S (1991) Rapid high-performance liquid chromatography assay for total homocysteine levels in human serum. Journal of Chromatography 565, 441–446.CrossRefGoogle ScholarPubMed
Ueland, PM, Refsum, H & Brattstrøm, L (1992) Plasma homocysteine and cardiovascular disease. In Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function, pp. 182 –222 [Francis, RBJ, editor]. New York: Marcel Dekker.Google Scholar
Upchurch, GR Jr, Welch, GN, Fabian, AJ, Freedman, JE, Johnson, JL, Keaney, JF Jr & Loscalzo, J (1997) Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. Journal of Biological Chemistry 272, 17012–17017.CrossRefGoogle ScholarPubMed
Usui, M, Matsuoka, H, Miyazaki, H, Ueda, S, Okuda, S & Imaizumi, T (1999) Endothelial dysfunction by acute hyperhomocysteinemia: restoration by folic acid. Clinical Science 96, 235–239.CrossRefGoogle ScholarPubMed
Wang, H, Yoshizumi, M, Lai, K, Tsai, JC, Perrella, MA, Haber, E & Lee, ME (1997) Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. Journal of Biological Chemistry 272, 25380–25385.CrossRefGoogle Scholar
Wilmink, W, Stroes, ESG, Erkelens, WD, Gerritsen, WB, Wever, R, Banga, J-D & Rabelink, TJ (2000) Influence of folic acid on postprandial endothelial dysfunction. Arteriosclerosis Thrombosis and Vascular Biology 20, 185–188.CrossRefGoogle ScholarPubMed
Woo, KS, Chook, P, Lolin, YI, Cheung, ASP, Chan, LT, Sun, YY, Sanderson, JE, Metreweli, C & Celermajer, DS (1997) Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96, 2542–2544.CrossRefGoogle ScholarPubMed
Woo, KS, Chook, P, Lolin, YI, Sanderson, JE, Metreweli, C & Celermajer, DS (1999) Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. Journal of American College of Cardiology 34, 2002–2006.CrossRefGoogle ScholarPubMed
Yoo, J-H & Lee, S-C (2001) Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158, 425–430.CrossRefGoogle ScholarPubMed